Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elham Askari

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
JMIR Formative Research|January 16, 2023
Feasibility of Telemedicine in the Management Strategy of Patients With Lymphoma Amid the COVID-19 Pandemic in Spain: Prospective Observational StudyRaul Cordoba, Alberto Lopez-Garcia, Daniel Morillo, et al.
Future Oncology (London, England)|July 26, 2023
Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myelomaAjai Chari, Elham Askari, Jo Caers, et al.
Plos One|November 12, 2020
Lymphoplasmacytic lymphoma associated with diffuse large B-cell lymphoma: Progression or divergent evolution?Macarena Boiza-Sánchez, Rebeca Manso, Olga Balagué, et al.
Hemasphere|November 13, 2024
Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter RegistryDavid F Moreno, Cristina Jiménez, Fernando Escalante, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|February 29, 2020
Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literatureRamón Lecumberri, Isabel Krsnik, Elham Askari, et al.
Disease Models & Mechanisms|July 26, 2023
Clonal architecture and evolutionary history of Waldenström's macroglobulinemia at the single-cell levelRamón García-Sanz, María García-Álvarez, Alejandro Medina, et al.
Cancers|June 10, 2023
Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in SpainJavier de la Rubia, Rafael Alonso, María Esther Clavero, et al.
Oncology and Therapy|December 12, 2022
Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)Adrián Alegre, Gonzalo Benzo, Rafael Alonso, et al.
Blood Cancer Journal|August 7, 2025
Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresisElham Askari, Angela Dispenzieri, Francis K Buadi, et al.
The New England Journal of Medicine|December 12, 2022
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple MyelomaAjai Chari, Monique C Minnema, Jesus G Berdeja, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
JMIR Formative Research|January 16, 2023
Feasibility of Telemedicine in the Management Strategy of Patients With Lymphoma Amid the COVID-19 Pandemic in Spain: Prospective Observational StudyRaul Cordoba, Alberto Lopez-Garcia, Daniel Morillo, et al.
Future Oncology (London, England)|July 26, 2023
Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myelomaAjai Chari, Elham Askari, Jo Caers, et al.
Plos One|November 12, 2020
Lymphoplasmacytic lymphoma associated with diffuse large B-cell lymphoma: Progression or divergent evolution?Macarena Boiza-Sánchez, Rebeca Manso, Olga Balagué, et al.
Hemasphere|November 13, 2024
Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter RegistryDavid F Moreno, Cristina Jiménez, Fernando Escalante, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|February 29, 2020
Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literatureRamón Lecumberri, Isabel Krsnik, Elham Askari, et al.
Disease Models & Mechanisms|July 26, 2023
Clonal architecture and evolutionary history of Waldenström's macroglobulinemia at the single-cell levelRamón García-Sanz, María García-Álvarez, Alejandro Medina, et al.
Cancers|June 10, 2023
Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in SpainJavier de la Rubia, Rafael Alonso, María Esther Clavero, et al.
Oncology and Therapy|December 12, 2022
Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)Adrián Alegre, Gonzalo Benzo, Rafael Alonso, et al.
Blood Cancer Journal|August 7, 2025
Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresisElham Askari, Angela Dispenzieri, Francis K Buadi, et al.
The New England Journal of Medicine|December 12, 2022
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple MyelomaAjai Chari, Monique C Minnema, Jesus G Berdeja, et al.
Pageof 6